- Conditions
- Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
- Interventions
- Questionnaire Administration, Trametinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced May 21, 2026, 7:41 PM EDT